Literature DB >> 12371586

Radical resections for T4 lung cancer.

Thomas W Rice1, Eugene H Blackstone.   

Abstract

T4 lung cancers are a heterogeneous group of locally advanced lung cancers. Treatment is palliative for the majority of patients, ranging from supportive care to chemoradiotherapy. In certain patients, however, surgery is beneficial and may be curative. Patients with T4N0M0 cancers invading the distal trachea, carina, left atrium, aorta, superior vena cava, or vertebral bodies may be surgical candidates. Radical resections of these T4 lung cancers have potential for cure if no mediastinal lymph node metastases (N2 or N3) occur and if resection is complete. Increased postoperative mortality exists and extends beyond 30 days, as evidenced by a 30-day mortality of 8% and a 90-day mortality of 18%. Improved palliation (median survival of 19 months) and cure (31% five-year survival) are possible in patients who meet the criteria, who undergo radical resection, and who are followed by physicians in facilities with special interests in extended resections. The use of induction therapy and surgery in T4 patients may further increase survival and the number of T4 patients in whom radical resection is possible. Radical resections are contraindicated in patients with T4 lung cancers associated with malignant pleural effusions. Unfortunately, these patients have the worst prognosis. If surgical palliation is an option, only pulmonary resection with pleurectomy and not pleuropneumonectomy should be considered. In contrast, lung cancers with the best prognosis are those T4 tumors diagnosed because of a satellite tumor nodule within the same lobe. Because radical resections are usually not required, operative mortality is not increased. Five-year survival in patients with satellite intralobar tumor nodules without mediastinal nodal metastases is comparable to survival of highly selected T4N0M0 patients who undergo radical resection. These two extremes of T4 lung cancers, malignant pleural effusion and satellite intralobar tumor nodules, generally are not considered for or do not require radical resections. It is debatable that the definition of T4 should include these entities.

Entities:  

Mesh:

Year:  2002        PMID: 12371586     DOI: 10.1016/s0039-6109(02)00017-8

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  9 in total

1.  Chest wall/parietal pleural invasions worsen prognosis in T4 non-small cell lung cancer patients after resection.

Authors:  Hiroshi Yabuki; Akira Sakurada; Shunsuke Eba; Fumihiko Hoshi; Hisashi Oishi; Yasushi Matsuda; Tetsu Sado; Masafumi Noda; Yoshinori Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-02-21

Review 2.  Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions.

Authors:  Carmen Vallejo Ocańa; Pilar Garrido López; Ignacio Muguruza Trueba
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

Review 3.  Extended resections of non-small cell lung cancers invading the aorta, pulmonary artery, left atrium, or esophagus: can they be justified?

Authors:  Emily S Reardon; David S Schrump
Journal:  Thorac Surg Clin       Date:  2014-09-11       Impact factor: 1.750

Review 4.  The technique of endoscopic airway tumor treatment.

Authors:  Simone Scarlata; Lello Fuso; Gabriele Lucantoni; Francesco Varone; Daniele Magnini; Raffaele Antonelli Incalzi; Gianni Galluccio
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

5.  [Extensive surgical resection in the treatment of invasive thymoma].

Authors:  José Galbis Caravajal; Jesús Sales Badía; Belén Viñals Larruga; Yolanda Pallardó Calatayud; Miguel Soler Tortosa; Antonio López Jimenez
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

Review 6.  Controversies regarding T status and N status for non-small cell lung cancer.

Authors:  Yanli Mo; Jiayin Peng; Wenmei Su; Xinggui Chen; Aibing Wu; Jinmei Li; Zhixiong Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Development of a rabbit pleural cancer model by using VX2 tumors.

Authors:  Kelly A Kreuter; Naglaa El-Abbadi; Alia Shbeeb; Lillian Tseng; Sari Brenner Mahon; Navneet Narula; Tanya Burney; Henri Colt; Matthew Brenner
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

8.  Surgical resection and survival of patients with unsuspected single node positive lung cancer (NSCLC) invading the descending aorta.

Authors:  Peter Wex; Thomas Graeter; Francesco Zaraca; Victor Haas; Steffen Decker; Hansanali Bugdayev; Heinrich Ebner
Journal:  Thorac Surg Sci       Date:  2009-07-14

Review 9.  Extracorporeal support for pulmonary resection: current indications and results.

Authors:  Petra Rosskopfova; Jean Yannis Perentes; Hans-Beat Ris; Fabrizio Gronchi; Thorsten Krueger; Michel Gonzalez
Journal:  World J Surg Oncol       Date:  2016-02-02       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.